Navigation Links
Microchip Biotechnologies, Inc. Enters Into License Arrangement With GE Healthcare for Fundamental Microfluidic Patents
Date:4/22/2008

DUBLIN, Calif., April 22 /PRNewswire/ -- Microchip Biotechnologies, Inc. (MBI) announces that it has entered into a multi-patent license agreement with GE Healthcare that significantly enhances MBI's intellectual property portfolio supporting the development of lab-on-a-chip devices. The patents cover design and methods for creating integrated fluidic microchip devices.

"Licensing these fundamental patents continues to build our strong intellectual property position in microfluidic devices," said Dr. Stevan Jovanovich, President and CEO of MBI. "Microfluidic devices will play a critical role in next-generation instrumentation that delivers fully-automated, cost-effective bioassay solutions in the life sciences, applied sciences, and molecular diagnostics."

California-based MBI will use the technology licensed from GE Healthcare to develop and commercialize easy to use Sample-To-Answer systems using advanced microfluidic technologies. Microfluidics deals with the behavior, precise control, and manipulation of microliter and nanoliter volumes of fluids to perform life science assays. Microfluidics technologies are essential for development of lab-on-a-chip devices for DNA analysis and molecular diagnostics. Microfluidic devices are smaller, faster and cheaper than the laboratory benchtop instruments that they are designed to replace, and are exquisitely suited for clinical and forensic systems used at the bedside or in the field.

About Microchip Biotechnologies

Microchip Biotechnologies, Inc. is an early-stage privately-held company located in Dublin, California that is developing advanced nanofluidic sample preparation and analytical instrumentation for Life Sciences, Applied Sciences, and Diagnostics markets. These solutions are based on MBI's proprietary "NanoBioProcessor(TM) platform and associated "Microscale-on-Chip-Valves" (MOV(TM)). More details can be found on the Company's website: '/>"/>

SOURCE Microchip Biotechnologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Canadian Centre for DNA Barcoding to Participate in Microchip Biotechnologies Early Access Program for Microchip-Based DNA Sample Preparation and Cycle Sequencing
2. Microchip Biotechnologies, Inc. Collaborating With Stanford University on Developing a Front End Microfluidic-Based Sample Preparation System for Pyrosequencing Platforms
3. Team develops energy-efficient microchip
4. Quick microchip test for dangerous antibiotic resistant bacteria
5. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
6. Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals
7. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
8. Millennium Biotechnologies, Inc. Launches SURGEX(TM) the First Scientifically Validated Sports Nutritional Product Created from the Medical Markets
9. Maven Biotechnologies, LLC to Present at BIOCOM Investor Conference
10. Alta Bates Summit Medical Center Opens Two Warm, Supportive Patient Centers: Carol Ann Read Breast Health Center and Family Resource Center
11. CyberKnife Radiosurgery Used to Treat Lung Tumors at 90 Percent of Centers Worldwide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... , Nov. 20, 2014 Polaris ... been dosed in its Phase 1 trial of ... for the treatment of malignant pleural mesothelioma (MPM) ... is conducting clinical trials on ADI-PEG 20, both ... for the treatment of several other indications, including ...
(Date:11/21/2014)... /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced ... 30, 2014.  Biorem,s complete 2014 third quarter financial statements and MD&A ... Summary:Three-months ended September 30, , Nine-months ended ... 2014 , 2013 , 2014 ... , 6,715 , 14,476 Gross profit , ...
(Date:11/18/2014)... New Orleans, LA (PRWEB) November 17, 2014 ... developer of build-to-order, open architecture blade-based and rackmount ... new NVIDIA® Tesla® K80 dual-GPU accelerator throughout its ... Utilizing a pair of the company’s latest proprietary ... up to eight discrete NVIDIA Tesla K80 dual-GPU ...
(Date:11/18/2014)... November 18, 2014 Alanda Software, ... Transparency Reporting solutions, announced today that a top ... its Consummate Provider™ solution in both the U.S. ... Global, SaaS based, Data Quality remediation portal, designed ... third party Providers improve their ability to capture, ...
Breaking Biology Technology:Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2Biorem Reports Third Quarter Results 2Biorem Reports Third Quarter Results 3Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 2Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 3Alanda Software Completes Successful Implementation of Global Data Quality & Vendor Management Solution for Top Tier Global Biopharmaceutical Company 2
... Inc. (Nasdaq: EXEL ) today announced that ... Inc. (Hudson, NY) pursuant to which Exelixis,sold Taconic ... GmbH,for approximately $20 million, subject to certain post-closing ... and commercialization of,genetically engineered mouse models and engineered ...
... LAKE, N.J., Nov. 20 Barr,Pharmaceuticals, Inc. (NYSE: ... Barr,Laboratories, Inc., has initiated a challenge of the ... 10mg, 15mg & 20mg. Focalin XR is manufactured ... Holdings Inc. Barr filed its Abbreviated New ...
... FRANKLIN, Mass., Nov. 20 Echo Therapeutics,Inc. (OTC ... quarter ended September 30, 2007. For the quarter ended ... share, compared to $1,390,000 or,$.49 per share, for the ... 30, 2007, net loss was $10,278,000, or $1.05 per ...
Cached Biology Technology:Exelixis Sells 80% Stake in Artemis to Taconic 2Exelixis Sells 80% Stake in Artemis to Taconic 3Exelixis Sells 80% Stake in Artemis to Taconic 4Barr Confirms Patent Challenge of Focalin(R) XR 2Barr Confirms Patent Challenge of Focalin(R) XR 3Echo Therapeutics Reports Third Quarter 2007 Results 2Echo Therapeutics Reports Third Quarter 2007 Results 3Echo Therapeutics Reports Third Quarter 2007 Results 4Echo Therapeutics Reports Third Quarter 2007 Results 5Echo Therapeutics Reports Third Quarter 2007 Results 6
(Date:11/3/2014)... Research and Markets has announced the addition of a ... to their offering. This report describes ... started to play an important role in the practice of ... bone marrow transplants. Role of cells in drug discovery is ... of medical practice. Stem cells are discussed in ...
(Date:11/3/2014)... Australia report that low birth weight and preterm birth ... replacements in adulthood. Findings published in the American College ... , indicate that low birth weight and pre-term babies ... to OA as adults. , According to the ... are diagnosed with clinical OA. Symptoms of OA range ...
(Date:11/2/2014)... was fascinating to put a flashlight up to our ... Washington University in St. Louis engineers are using a ... to improve imaging of cancerous tissues and to develop ... K. Beare Distinguished Professor of Biomedical Engineering at the ... novel time-reversal technology that allows researchers to better focus ...
Breaking Biology News(10 mins):Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3Preterm, low birth-weight babies may need new hips in adulthood 2Improving imaging of cancerous tissues by reversing time 2
... Louis, MO, May 11, 2009 As the childhood obesity ... early parent and child behaviors contribute to the problem. A ... in the May/June 2009 issue of the Journal of ... signs of satiety in their infants tend to overfeed them, ...
... world,s second largest fish hide out for half ... on May 7th in Current Biology , a ... the iconic species and highlights just how little we ... the researchers said. "While commonly sighted in surface ...
... team of researchers from the United States, the Netherlands ... that are associated with altered kidney disease risk. One ... protein, the most common protein in the urine of ... for almost 60 years, its functions are not well ...
Cached Biology News:Does mom know when enough is enough? 2Disappearing act of world's second largest fish explained 2Study finds novel genetic risk factors for kidney disease 2
... HistoMark Biotin Streptavidin-HRP Systems provide ... and intracellular antigens in frozen or ... These systems also facilitate double ... can be performed simultaneously with primary ...
Screening test for the detection of Salmonella sp. by means of DNA amplification, subsequent molecular hybridization and detection on a microtitre plate....
... three step procedure (PCR, Exonuclease III digestion ... one day. The typical cloning efficiency using ... Features and Benefits: , , Universal - ... expression vector , High Cloning Efficiency - ...
... Two sizes available for use with 96- or 384-well ... 96 for ease of location on 96-tube plates ... the skirt of the plate* Efficient sealing is ... in conjunction with screw or clip-down hot lid thermal ...
Biology Products: